Classement en actions
#10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Prix de l'action
$14.66
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$839.37M
Changement (1 jour)
-2.67%
Changement (1 an)
557.32%
Échange Climb Bio, Inc. (CLYM)
Le prix CLYM avec la capitalisation boursière de B
Capitalisation boursière de Climb Bio, Inc.(CLYM)
Capitalisation boursière: $839.37M
En August 2026, Climb Bio, Inc. a une capitalisation boursière de $839.37M. Cela fait de Climb Bio, Inc. la 10440th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Climb Bio, Inc. du 2024 au 2026
CLYM par rapport au top 5 des plus populaires stocks
| Prix pour CLYM |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.264T
|
+627,019.37%
|
|
|
|
|
$4.701T
|
+559,994.09%
|
|
|
|
|
$4.177T
|
+497,554.81%
|
|
|
|
|
$3.817T
|
+454,692.24%
|
|
|
|
|
$2.866T
|
+341,385.66%
|
